Deal Snapshot: Using antibodies against an undisclosed target discovered and engineered by Innate, Takeda plans to investigate the potential of antibody-drug conjugates in celiac disease

While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.

Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.

Industry veteran Tadataka Yamada draws on his multidisciplinary background for perspectives on what’s new – and what isn’t – in a field where every researcher has at some point experienced the same teachable moment:  when you strive to make a medicine, so many things can go wrong.